NEW YORK – A significant gap in the clinical delivery of care for wet age-related macular degeneration (wAMD) has emerged, with nearly 40% of patients remaining untreated for 180 days within the first year of diagnosis.
The findings, presented at the ASRS 2026 meeting, highlight a systemic failure in the patient pathway that persists despite the availability of advanced therapeutic interventions. For a condition where rapid treatment is critical to preventing permanent vision loss, this delay represents a substantial misalignment between pharmaceutical innovation and healthcare execution.
The inability to transition patients from diagnosis to treatment efficiently impacts the economic utility of the FDA-approved drug pipeline and increases the long-term cost of care for aging populations. It also raises questions for payers and policymakers about whether current reimbursement and delivery structures are capable of translating public and private investment in ophthalmic innovation into real-world vision outcomes.
Clinical Delivery Failures in wAMD
The data indicates that a large segment of the wAMD population faces prolonged intervals without therapeutic intervention during the most critical phase of the disease. This 180-day treatment void occurs despite the established standard of care requiring prompt and often repeated intravitreal injections to stabilize vision and prevent further retinal damage.
The delay in treatment often correlates with poorer visual outcomes, which increases the dependency of patients on social services and healthcare infrastructure and accelerates the shift from partial impairment to functional blindness.
- Treatment Gap: Nearly 40% of patients remain untreated for 180 days in the first year after diagnosis.
- Critical Window: The first year post-diagnosis is widely regarded by clinicians as the most vital for preserving central vision and maintaining independence.
- Primary Outcome Risk: Delayed intervention significantly increases the likelihood of irreversible retinal damage and permanent loss of driving and reading vision.
“The fact that nearly 40% of patients are going untreated for six months in their first year is a call to action for the retina community to examine where the breakdowns are occurring in our referral and treatment pathways.”
Clinicians at the meeting described the pattern as a “silent attrition” of newly diagnosed patients who never complete the transition from initial detection to sustained therapy, despite being technically eligible for treatment.
Market and Policy Implications for Anti-VEGF Therapies
The persistence of this treatment gap occurs within a high-value pharmaceutical sector dominated by anti-VEGF therapy. Market leaders including Regeneron and Roche have invested billions into developing agents such as Eylea and Vabysmo to extend the intervals between injections, reduce clinic chair time and lower the cumulative burden on both patients and providers.
However, the efficacy and health-economic promise of these long-acting agents is predicated on the patient entering – and remaining in – the treatment cycle. The current data suggests that a significant portion of the addressable market is not accessing these therapies in a timely manner, regardless of the drug’s duration of action or label indication.
For payers and health systems, this inefficiency suggests that the primary bottleneck in the wAMD market has shifted from pharmacological limitations to operational and systemic barriers within the healthcare delivery chain. It also undermines forecasts for drug uptake and challenges assumptions behind value-based contracts that tie reimbursement to real-world outcomes.
Systemic Barriers to Patient Access
The gap in care is frequently attributed to frictions in the referral process between primary optometrists, comprehensive ophthalmologists and retina specialists. In many healthcare systems, the transition from the initial detection of fluid in the macula to the first intravitreal injection is hindered by scheduling delays, fragmented electronic records and prior-authorization requirements from public and commercial insurers.
These access hurdles sit within a broader regulatory environment in which ophthalmic drugs and devices are overseen not only at the product-approval stage but across their life cycle by agencies such as the Center for Drug Evaluation and Research, which shapes labeling, risk management and, indirectly, patterns of clinical use.
The economic burden of untreated wAMD is significant, as permanent blindness often results in loss of employment, increased need for caregiving and higher long-term care costs for governments, private insurers and families. The resulting demand for disability benefits, home modifications and assisted-living support extends the impact well beyond specialty eye care.
The failure to capture nearly 40% of the patient population for six months indicates a breakdown in the “patient journey,” affecting the overall return on investment of specialized ophthalmology clinics and the projected uptake of new therapeutic entries. Hospital systems and integrated delivery networks face a dual hit: underutilized high-cost infusion capacity and downstream costs associated with avoidable vision loss.
Current clinical protocols remain heavily focused on what to do once a patient is on the injection schedule – choice of agent, dosing interval, monitoring frequency – while the operational challenge of patient identification, acquisition and onboarding remains unresolved and largely unmeasured.
As a result, the current market condition for wAMD therapeutics is characterized by high pharmaceutical efficacy paired with low systemic delivery efficiency. All current anti-VEGF agents remain subject to standard regulatory monitoring for safety and efficacy, but the emerging evidence suggests that regulatory approval alone is insufficient to guarantee population-level benefit without parallel reforms in referral pathways, coverage policies and real-world implementation.
Keep reading
